Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
AssigneeThe General Hospital Corporation
InventorsGuy L. Reed, Edgar Haber, Gary R. Matsueda
Life of this patent
Estimating the term…
Abstract
The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to α2-antiplasmin crosslinked to fibrin (α2AP-FX) which does not inhibit plasma α2-antiplasmin (α2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward α2-antiplasmin crosslinked to fibrin which does not inhibit plasma α2AP together with a thrombolytic agent.
Claims10
A monoclonal antibody or fragment thereof wherein said antibody or fragment thereof is specific to an epitope formed by the crosslinking of α2-antiplasmin to fibrin and inhibits α2-antiplasmin crosslinked to fibrin so as to increase endogenous fibrinolysis but does not interfere with the inactivation of circulating plasmin by soluble α2-antiplasmin.
A kit useful for carrying out a method of treatment for myocardial infarction or blood clots within a patient which comprises co-administering to said patient:
- (a) an antibody or fragment thereof which is specific to an epitope formed by the crosslinking of α2-antiplasmin to fibrin and inhibits α2-antiplasmin crosslinked to fibrin so as to increase endogenous fibrinolysis but does not interfere with the inactivation of circulating plasmin by soluble α2-antiplasmin, in a therapeutically effective amount;
- and
- (b) a thrombolytic agent in an amount sufficient to either (i) dissolve a fibrin or fibrin-platelet clot or (ii) inhibit the formation of a fibrin or fibrin-platelet clot, comprising a carrier means being compartmentalized in close confinement to receive two or more container means therein, which comprises:
- (1) a first container means containing a therapeutically effective amount of said antibody or fragment thereof (a);
- and
- (2) a second container containing a therapeutically effective amount of said thrombolytic agent (b).
A monoclonal antibody or fragment thereof wherein said antibody or fragment thereof is specific to an epitope formed by the crosslinking of α2-antiplasmin to fibrin and inhibits α2-antiplasmin crosslinked to fibrin so as to increase endogenous fibrinolysis, and wherein the mean inhibition of soluble or plasma α2-antiplasmin by said antibody or fragment thereof, as measured using a chromogenic substrate assay, is about equal to or less than that of monoclonal antibody 1F2 (ATCC HB-12149).
Dependencies are inferred from the claim text.